Who’s Who with Recce Pharmaceuticals: Fighting on a crucial front for the health sector

Host Tylah Tully looks at Recce Pharmaceuticals (ASX:RCE) in the latest episode of Who’s Who on the ASX.

Recce is a clinical-stage biotech company focused on developing a new class of synthetic anti-infectives.

In particular, the company is tackling the nasties resistant to the antibiotics, antivirals, antifungals, and antiparasitic drugs essential for preventing and treating infections.

Watch the video to learn more.

This video was developed in collaboration with Recce Pharmaceuticals, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.